Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014.

IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-22 DOI:10.1080/21645515.2024.2378537
Adriana Efron, Alessandro Brozzi, Alessia Biolchi, Margherita Bodini, Maria Giuliani, Silvia Guidotti, Federico Lorenzo, María Alicia Moscoloni, Alessandro Muzzi, Florencia Nocita, Mariagrazia Pizza, Rino Rappuoli, Sara Tomei, Gabriela Vidal, Carla Vizzotti, Josefina Campos, Cecilia Sorhouet Pereira
{"title":"Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 <i>Neisseria meningitidis</i> isolates causing invasive meningococcal disease in Argentina in 2010-2014.","authors":"Adriana Efron, Alessandro Brozzi, Alessia Biolchi, Margherita Bodini, Maria Giuliani, Silvia Guidotti, Federico Lorenzo, María Alicia Moscoloni, Alessandro Muzzi, Florencia Nocita, Mariagrazia Pizza, Rino Rappuoli, Sara Tomei, Gabriela Vidal, Carla Vizzotti, Josefina Campos, Cecilia Sorhouet Pereira","doi":"10.1080/21645515.2024.2378537","DOIUrl":null,"url":null,"abstract":"<p><p>Meningococcal (<i>Neisseria meningitidis</i>) serogroup B (MenB) strain antigens are diverse and a limited number of strains can be evaluated using the human serum bactericidal antibody (hSBA) assay. The genetic Meningococcal Antigen Typing System (gMATS) was developed to predict the likelihood of coverage for large numbers of isolates by the 4CMenB vaccine, which includes antigens <i>Neisseria</i> adhesin A (NadA), Neisserial Heparin-Binding Antigen (NHBA), factor H-binding protein (fHbp), and Porin A (PorA). In this study, we characterized by whole-genome analyses 284 invasive MenB isolates collected from 2010 to 2014 by the Argentinian National Laboratories Network (52-61 isolates per year). Strain coverage was estimated by gMATS on all isolates and by hSBA assay on 74 randomly selected isolates, representative of the whole panel. The four most common clonal complexes (CCs), accounting for 81.3% of isolates, were CC-865 (75 isolates, 26.4%), CC-32 (59, 20.8%), CC-35 (59, 20.8%), and CC-41/44 (38, 13.4%). Vaccine antigen genotyping showed diversity. The most prevalent variants/peptides were fHbp variant 2, NHBA peptides 24, 21, and 2, and PorA variable region 2 profiles 16-36 and 14. The <i>nadA</i> gene was present in 66 (23.2%) isolates. Estimated strain coverage by hSBA assay showed 78.4% of isolates were killed by pooled adolescent sera, and 51.4% and 64.9% (based on two different thresholds) were killed by pooled infant sera. Estimated coverage by gMATS (61.3%; prediction interval: 55.5%, 66.7%) was consistent with the infant hSBA assay results. Continued genomic surveillance is needed to evaluate the persistence of major MenB CCs in Argentina.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2378537"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2378537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Meningococcal (Neisseria meningitidis) serogroup B (MenB) strain antigens are diverse and a limited number of strains can be evaluated using the human serum bactericidal antibody (hSBA) assay. The genetic Meningococcal Antigen Typing System (gMATS) was developed to predict the likelihood of coverage for large numbers of isolates by the 4CMenB vaccine, which includes antigens Neisseria adhesin A (NadA), Neisserial Heparin-Binding Antigen (NHBA), factor H-binding protein (fHbp), and Porin A (PorA). In this study, we characterized by whole-genome analyses 284 invasive MenB isolates collected from 2010 to 2014 by the Argentinian National Laboratories Network (52-61 isolates per year). Strain coverage was estimated by gMATS on all isolates and by hSBA assay on 74 randomly selected isolates, representative of the whole panel. The four most common clonal complexes (CCs), accounting for 81.3% of isolates, were CC-865 (75 isolates, 26.4%), CC-32 (59, 20.8%), CC-35 (59, 20.8%), and CC-41/44 (38, 13.4%). Vaccine antigen genotyping showed diversity. The most prevalent variants/peptides were fHbp variant 2, NHBA peptides 24, 21, and 2, and PorA variable region 2 profiles 16-36 and 14. The nadA gene was present in 66 (23.2%) isolates. Estimated strain coverage by hSBA assay showed 78.4% of isolates were killed by pooled adolescent sera, and 51.4% and 64.9% (based on two different thresholds) were killed by pooled infant sera. Estimated coverage by gMATS (61.3%; prediction interval: 55.5%, 66.7%) was consistent with the infant hSBA assay results. Continued genomic surveillance is needed to evaluate the persistence of major MenB CCs in Argentina.

2010-2014 年阿根廷 284 株引起侵袭性脑膜炎球菌病的奈瑟氏脑膜炎球菌分离株的遗传特征和估计 4CMenB 疫苗菌株覆盖率。
脑膜炎球菌(奈瑟氏脑膜炎球菌)血清 B 群(MenB)菌株抗原多种多样,使用人血清杀菌抗体 (hSBA) 检测法可评估的菌株数量有限。基因脑膜炎球菌抗原分型系统(gMATS)的开发是为了预测 4CMenB 疫苗覆盖大量分离株的可能性,其中包括抗原奈瑟氏粘附素 A (NadA)、奈瑟氏肝素结合抗原 (NHBA)、H 结合因子蛋白 (fHbp) 和茯苓蛋白 A (PorA)。在这项研究中,我们通过全基因组分析对阿根廷国家实验室网络从 2010 年至 2014 年收集的 284 株侵袭性 MenB 分离物(每年 52-61 株)进行了鉴定。通过 gMATS 对所有分离株进行了菌株覆盖率评估,并通过 hSBA 检测对随机挑选的 74 个分离株进行了菌株覆盖率评估,这 74 个分离株在整个分析小组中具有代表性。最常见的四个克隆复合体(CC)占分离株的 81.3%,分别是 CC-865(75 株,26.4%)、CC-32(59 株,20.8%)、CC-35(59 株,20.8%)和 CC-41/44(38 株,13.4%)。疫苗抗原基因分型显示出多样性。最常见的变体/肽是 fHbp 变体 2、NHBA 肽 24、21 和 2,以及 PorA 可变区 2 剖面 16-36 和 14。有 66 个(23.2%)分离株含有 nadA 基因。通过 hSBA 检测估计的菌株覆盖率显示,78.4% 的分离株被汇集的青少年血清杀死,51.4% 和 64.9%(基于两种不同的阈值)的分离株被汇集的婴儿血清杀死。gMATS 的估计覆盖率(61.3%;预测区间:55.5%,66.7%)与婴儿 hSBA 检测结果一致。需要继续进行基因组监测,以评估阿根廷主要男童乙型脑炎的持续情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
CiteScore
7.90
自引率
8.30%
发文量
489
审稿时长
3-6 weeks
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信